Lupin's Brazilian subsidiary acquires rights to nine brands from Bausch Health

28 Nov 2022 Evaluate

Lupin’s wholly owned subsidiary in Brazil, Medquimica Industria Farmaceutica (MedQuimica), has signed a definitive agreement to acquire all rights to nine medicines from BL Industria Otica, a subsidiary of Bausch Health Companies Inc. As part of the transaction, MedQuimica will acquire rights to nine products including Limbitrol, Melleril and Dalmadorm for Central Nervous System related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle and Efurix as topical oncological treatments, and Cuprimine for the treatment of Wilson’s disease. This move reinforces the company’s commitment to making healthcare solutions accessible to all patients.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2177.20 0.95 (0.04%)
19-Jan-2026 11:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1680.55
Dr. Reddys Lab 1171.00
Cipla 1385.80
Zydus Lifesciences 866.65
Lupin 2177.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×